Compare AJANTA PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FRESENIUS KABI ONCO. AJANTA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 23.5 22.1 106.3% View Chart
P/BV x 4.1 3.1 133.2% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 AJANTA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,422176 807.9%   
Low Rs89879 1,143.4%   
Sales per share (Unadj.) Rs233.537.7 619.6%  
Earnings per share (Unadj.) Rs44.05.1 863.2%  
Cash flow per share (Unadj.) Rs52.26.7 775.7%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.142.5 599.6%  
Shares outstanding (eoy) m88.02158.23 55.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.4 147.1%   
Avg P/E ratio x26.425.0 105.6%  
P/CF ratio (eoy) x22.218.9 117.5%  
Price / Book Value ratio x4.53.0 152.0%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,08120,135 507.0%   
No. of employees `0006.81.2 590.3%   
Total wages/salary Rs m4,307703 612.5%   
Avg. sales/employee Rs Th3,022.65,176.2 58.4%   
Avg. wages/employee Rs Th633.4610.4 103.8%   
Avg. net profit/employee Rs Th569.1699.6 81.3%   
INCOME DATA
Net Sales Rs m20,5545,963 344.7%  
Other income Rs m21118 1,171.1%   
Total revenues Rs m20,7655,981 347.2%   
Gross profit Rs m5,6641,430 396.1%  
Depreciation Rs m721258 279.5%   
Interest Rs m12-26 -44.6%   
Profit before tax Rs m5,1431,216 422.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,273342 372.0%   
Profit after tax Rs m3,870806 480.2%  
Gross profit margin %27.624.0 114.9%  
Effective tax rate %24.828.1 88.0%   
Net profit margin %18.813.5 139.3%  
BALANCE SHEET DATA
Current assets Rs m11,8125,102 231.5%   
Current liabilities Rs m3,7762,385 158.3%   
Net working cap to sales %39.145.6 85.8%  
Current ratio x3.12.1 146.3%  
Inventory Days Days77150 51.6%  
Debtors Days Days82113 72.0%  
Net fixed assets Rs m14,3985,148 279.7%   
Share capital Rs m175158 110.9%   
"Free" reserves Rs m22,2776,556 339.8%   
Net worth Rs m22,4526,732 333.5%   
Long term debt Rs m7952 0.7%   
Total assets Rs m26,96210,388 259.5%  
Interest coverage x444.3-45.8 -970.7%   
Debt to equity ratio x00.1 0.2%  
Sales to assets ratio x0.80.6 132.8%   
Return on assets %14.47.5 191.7%  
Return on equity %17.212.0 144.0%  
Return on capital %23.014.6 157.2%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m10,6825,298 201.6%   
Fx outflow Rs m2,1021,772 118.6%   
Net fx Rs m8,5803,525 243.4%   
CASH FLOW
From Operations Rs m3,7481,274 294.2%  
From Investments Rs m-2,228-1,204 185.0%  
From Financial Activity Rs m-1,475-196 752.0%  
Net Cashflow Rs m45-126 -35.8%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 9.6 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 42,599 49.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS